Oct 8 (Reuters) - CSL Ltd CSL.AX :
* FINALISES AGREEMENT TO SUPPLY 51 MILLION DOSES OF UQ COVID-19 VACCINE CANDIDATE TO AUSTRALIA
* LARGE-SCALE PHASE 2B/3 CLINICAL STUDY FOR V451 IS ALMOST READY
* FINALISES AGREEMENT FOR SUPPLY, SHOULD CLINICAL TRIALS BE SUCCESSFUL
* AGREEMENT INCLUDES FINANCIAL COMMITMENT FROM GOVERNMENT TO SUPPORT CLINICAL DEVELOPMENT NEEDED IN ORDER TO PROGRESS V451
* WORKING TO ENGAGE PARTNER ORGANISATIONS TO ASSIST WITH PRODUCTION OF FURTHER DOSES WITH GOAL OF PROVIDING BROADER ACCESS TO VACCINE
* TOO EARLY TO CALCULATE WITH ANY CERTAINTY FINANCIAL IMPACT TO COMPANY
* IF CLINICAL TRIALS ARE SUCCESSFUL, AGREEMENT ALSO SECURES ACCESS TO ONSHORE PRODUCTION AND SUPPLY OF VACCINE FOR AUSTRALIA